Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Coherus Oncology's Total Liabilities for the quarter that ended in Jun. 2026 was €113.14 Mil. Coherus Oncology's Total Assets for the quarter that ended in Jun. 2026 was €165.95 Mil.
Therefore, Coherus Oncology's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2026 was 0.68.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Coherus Oncology Liabilities-to-Assets Related Terms
Coherus Oncology Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for Coherus Oncology's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8C5 vs VYGR, KROS, DTIL: Liabilities-to-Assets Comparison
For the Biotechnology subindustry, Coherus Oncology's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus Oncology Liabilities-to-Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus Oncology's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Coherus Oncology's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Coherus Oncology's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coherus Oncology (FRA:8C5) has a Liabilities-to-Assets of 0.68 as of Jun. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Coherus Oncology and its competitors.
Is Coherus Oncology's Liabilities-to-Assets too high?
Coherus Oncology's current Liabilities-to-Assets is 0.68. Overall, Coherus Oncology has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's Liabilities-to-Assets compare to VYGR and KROS?
Coherus Oncology's Liabilities-to-Assets of 0.68 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Biotechnology company?
A good Liabilities-to-Assets depends on the Biotechnology industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Coherus Oncology and its competitors. Coherus Oncology's current Liabilities-to-Assets is 0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Coherus Oncology (FRA:8C5) has a current Liabilities-to-Assets of 0.68. The stock's GF Value™ is €0.92, compared to a current price of €1.16 — trading 26.3% above its estimated fair value. The current Liabilities-to-Assets is 0.68. Coherus Oncology's overall GF Score™ is 57/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current Liabilities-to-Assets is 0.68 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coherus Oncology (FRA:8C5) Overvalued in 2026?
Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued.
The current stock price of €1.16 is trading 26.3% above its estimated GF Value™ of €0.92.
Key valuation signals for FRA:8C5:
Liabilities-to-Assets: 0.68
GF Value™: €0.92 vs. price of €1.16 (26.3% above fair value)
No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
57GF Score
Get the complete analysis for FRA:8C5
Liabilities-to-Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8C5 has been successfully added to your 
